Market capitalization | $125.95m |
Enterprise Value | $99.91m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 7.50 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-13.63m |
Free Cash Flow (TTM) Free Cash Flow | $-11.20m |
Cash position | $26.04m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
3 Analysts have issued a Medicenna Therapeutics Corp forecast:
3 Analysts have issued a Medicenna Therapeutics Corp forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.01 -0.01 |
-
|
|
EBITDA | -14 -14 |
11%
11%
|
EBIT (Operating Income) EBIT | -14 -14 |
11%
11%
|
Net Profit | -19 -19 |
198%
198%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company which engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.
Head office | Canada |
CEO | Fahar Merchant |
Employees | 16 |
Founded | 2015 |
Website | www.medicenna.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.